Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma

Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma

High recurrence rates and poor survival of patients with esophageal squamous cell carcinoma (ESCC) after treatment make ongoing research on chemoprevention drugs for ESCC particularly important. In this study, we screened a large number of FDA-approved drugs and found levodopa, a drug used to treat...

Full description

Bibliographic Details
Main Authors: Zhenzhen Li, Xin Li, Xinyu He, Xuechao Jia, Xiaofan Zhang, Bingbing Lu, Jimin Zhao, Jing Lu, Lexia Chen, Ziming Dong, Kangdong Liu, Zigang Dong
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Pharmacology
Subjects:
esophageal squamous cell carcinoma
levodopa
proteomic
mitochondria
succinate dehydrogenase subunit D
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.568459/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.568459/full

Similar Items